Sinopharm Starts Talks With Provectus Over Anticancer
This article was originally published in PharmAsia News
Executive Summary
Sinopharm has signed an MoU with the U.S. bioventure Provectus to begin talks on licensing in an anticancer molecule, speeding up its planned expansion in the China oncology sector.